Search

Displaying results 991 - 1000 of 7479 in total
  1. Drug

    Camizestrant

    go.drugbank.com/drugs/DB19218
    ApprovedInvestigational

    [L64094,L64107] In pre- or peri-menopausal women and in men, camizestrant plus a CDK4/6 inhibitor is combined with an LHRH agonist or antagonist. … Camizestrant is an oral selective estrogen receptor degrader (SERD) and estrogen receptor (ER) antagonist used in combination with a CDK4/6 inhibitor to treat hormone receptor-positive, HER2-negative locally

  2. Drug

    Niclosamide

    go.drugbank.com/drugs/DB06803
    ApprovedInvestigationalVet approved

    Niclosamide is an antihelminthic used for the treatment of tapeworm infections. … They are an even greater problem in domestic animals. Niclosamide, once marketed in the US under the brand name Niclocide, was voluntarily withdrawn from market by Bayer in 1996.[L11860]

  3. Drug

    Polihexanide

    go.drugbank.com/drugs/DB12277
    ApprovedInvestigational

    [A1351,A273908] Polihexanide is approved in Europe under the name Akantior for the treatment of _Acanthamoeba_ keratitis, an ocular infection caused by the _Acanthamoeba_ parasite.

  4. Drug

    Etranacogene dezaparvovec

    go.drugbank.com/drugs/DB16791
    ApprovedInvestigational

    [L44161] Men are most likely to experience symptomatic illness due to the X-linked provenance of the disorder. … Hemophilia B - also called factor IX deficiency or Christmas disease - is an X-linked genetic disorder resulting in an absence or deficiency of clotting factor IX.

  5. Drug

    Cerivastatin

    go.drugbank.com/drugs/DB00439
    ApprovedWithdrawn

    Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from

  6. Drug

    Gefapixant

    go.drugbank.com/drugs/DB15097
    Approved

    [L48596,L48591] It is the first therapy to be approved for the treatment of RCC or UCC in the EU.[L48601] … investigation and treatment, termed refractory chronic cough (RCC) if they have a cough that does not respond to conventional treatment or unexplained chronic cough (UCC) when no diagnosable cause for the cough can

  7. Drug

    Simoctocog alfa

    go.drugbank.com/drugs/DB09108
    Approved

    It is an antihemorrhagic agent used as a replacement therapy in individuals with Haemophilia A who lack the factor VIII in the intrinsic pathway of blood coagulation system. … As patients with haemophilia A are predisposed to episodes of recurrent bleeding [L1115], simoctocog alfa can be administered for the treatment or prevention of bleeding such as prior to surgical procedures

  8. Drug

    Lacidipine

    go.drugbank.com/drugs/DB09236
    Approved

    Due to its long duration of action, lacidipine does not lead to reflex tachycardia [A31536]. … Lacidipine is a lipophilic dihydropyridine calcium antagonist with an intrinsically slow onset of activity.

  9. Drug

    Echothiophate

    go.drugbank.com/drugs/DB01057
    ApprovedInvestigational

    A potent, long-acting irreversible cholinesterase inhibitor used as an ocular hypertensive in the treatment of glaucoma. Occasionally used for accomodative esotropia.

  10. Drug

    Ubidecarenone

    go.drugbank.com/drugs/DB09270
    ApprovedInvestigationalNutraceutical

    Ubidecarenone, also called coenzyme Q10, is a 1,4-benzoquinone. From its name (Q10), the Q refers to the constitutive quinone group, and 10 is related to the number of isoprenyl subunits in its tail. It is a powerful antioxidant, a lipid...

    Mixtures: Coq10 With E400 Iu, Coen.q10w.vit.c and E Beta-car.se Cu Zn Mn